Background: Arrhythmogenic cardiomyopathy (ACM) is a heritable cardiac disease characterized by arrhythmias, progressive myocardial injury, and sudden death. Inflammation is central to disease progression. 2-deoxy-2-[18F]-Fluoroglucose positron emission tomography ([18F]FDG PET) is increasingly used to identify glycolytically active immune cells in inflammatory cardiomyopathies. However, whether [18F]FDG uptake in ACM reflects myocardial immune cell recruitment remains unclear. Methods and Results: We performed cardiac [18F]FDG PET imaging in wild-type and desmoglein-2 (DSG2) mutant mice, a well established model of ACM, followed by immune cell profiling using flow cytometry. DSG2 mutant mice exhibited significantly increased cardiac [18F]FDG uptake compared with wild type controls. Although both CCR2+ and CCR2- macrophage populations correlated with the [18F]FDG uptake, pharmacologic depletion of macrophages with liposomal clodronate did not reduce [18F]FDG uptake. High resolution confocal microscopy using the fluorescent glucose analog 2-NBDG demonstrated increased uptake localized predominantly to cardiomyocytes in DSG2 mutant hearts.Conclusions: Myocardial [18F]FDG uptake is not dependent on macrophage abundance and is predominantly localized to cardiomyocytes. These findings suggest that [18F]FDG uptake reflects cardiomyocyte metabolic remodeling driven by cell-intrinsic inflammatory signaling pathways, rather than serving as a direct marker of immune cell infiltration.